

Working Memory (WM) training: A randomised controlled treatment study in young ADHD children.

Published: 08-12-2008

Last updated: 06-05-2024

Objective: 1) To investigate the efficacy of WM training in reducing behavioral symptoms in young children with ADHD.2) To investigate whether WM training improves neurocognitive functioning in young children with ADHD.3) To investigate whether WM...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Cognitive and attention disorders and disturbances
Study type	Interventional

Summary

ID

NL-OMON32875

Source

ToetsingOnline

Brief title

Working Memory training in ADHD children

Condition

- Cognitive and attention disorders and disturbances

Synonym

ADHD, attention disorder

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Sint Radboud

Source(s) of monetary or material Support: Smartmix fonds

Intervention

Keyword: ADHD, children, Working memory training

Outcome measures

Primary outcome

Main study parameter/endpoint: ADHD-DSM-IV rating scale rated by the investigator.

Secondary outcome

Neurocognitive functioning in young children with ADHD

Neural functioning in young children with ADHD

Study description

Background summary

Rationale: WM training has been shown to offer therapeutic benefits to patients with ADHD in several studies, but methodological shortcomings indicate that additional research is needed. This study is designed to examine the efficacy of WM training in a scientific rigorous way in young ADHD children.

Study objective

Objective:

- 1) To investigate the efficacy of WM training in reducing behavioral symptoms in young children with ADHD.
- 2) To investigate whether WM training improves neurocognitive functioning in young children with ADHD.
- 3) To investigate whether WM training improves neural functioning in young children with ADHD.

Study design

Double-blind randomised controlled treatment study.

Intervention

Intervention: 50 subjects receive 25 sessions WM training and 50 subjects receive 25 sessions of the control version of WM training.

Study burden and risks

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Risks or side-effects are not expected. The burden for the subjects consists of an intake, pre- and post-treatment assessments, the training itself consisting of 25 sessions for 15 minutes, an evaluation and a follow-up. The intake, pre-assessment, training and evaluation carry the same burden as treatment as usual. The benefit involves of the a priori chance of positive effect of the WM training on ADHD symptoms. Because ADHD is primarily a psychiatric disorder of childhood, children will form the target population of the present study.

Contacts

Public

Universitair Medisch Centrum Sint Radboud

Reinier Postlaan 12, Karakter University Nijmegen
6525 GC Nijmegen
NL

Scientific

Universitair Medisch Centrum Sint Radboud

Reinier Postlaan 12, Karakter University Nijmegen
6525 GC Nijmegen
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Children (2-11 years)

Inclusion criteria

Age between 4 years/6 months and 7 years/4 months

Diagnosis ADHD, classified by the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 2000)

A full scale IQ > 80 ;Psychopharmaca- naïve or -free;Access to a PC with Windows Vista or Windows XP with internet connection and speakers at home

Exclusion criteria

Currently intensive (i.e. weekly) individual or group psychotherapy

Regular use of other medication

Comorbid psychiatric disorders other than Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS).

Neurological disorders (e.g. epilepsy) currently or in the past

Cardiovascular disease currently or in the past

Serious motor or perceptual handicap

Participation in another clinical trial simultaneously

Educational level and/ or socio-economic situation that makes it unlikely for the family to fulfil this study

Study design

Design

Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Double blinded (masking used)
Control:	Placebo
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Recruitment stopped
Start date (anticipated):	01-06-2009
Enrollment:	100

Type: Actual

Ethics review

Approved WMO

Date: 08-12-2008

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL24290.091.08

Study results

Date completed: 01-01-2014

Actual enrolment: 51